Glaxosmithkline Biologicals Sa

Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

J. Craig Venter Institute

Chiron Corporation

Novartis Vaccines and Diagnostics Srl

Sclavo Spa

Chiron S.r.l.

Cesira Galeotti

Mariagrazia Pizza

Vega Masignani

Maria Scarselli

Vincenzo Scarlato

Guido Grandi

Rino Rappuoli

Marirosa Mora

Claire M Fraser

Herve Tettelin

Erin Hickey

Giulio Ratti

Jeremy Petersen

J Craig Venter

Maurizio Comanducci

Giuliano Bensi

Maria Arico

Catherine Greer

Roberto Petracca

Guilio Ratti

Daniela Tornese Buonamassa

Marzia Monica Giuliani

Maria Aricò

Mariarosa Mora

Marizia Monica Guiliani

Manuele Martinelli

Maria Beatrice Arico

Hervé Tettelin

Rosanna Leuzzi

Craig Venter

Craig Ventor

Maria L Melli

Emanuela Palla

Giovanni Raugei

Marzia Monica Guiliani

Maria Rosa Mora

Meera Unnikrishnan

Giulo Ratti

Jeremy D Peterson

Mariagratia Pizza

Enzo Scalato

Maria B Arico

The invention provides methods, proteins, nucleic acids and antibodies for preventing or treating ainfection in a mammal.

Clostridium difficile polypeptides as vaccine

Two or more Neisserial proteins (e.g. A and B) are expressed as a single hybrid protein which can be represented simply by the formula NH-A-B&#x2014;COOH.

Hybrid expression of neisserial proteins

The invention provides proteins from, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

[object Object]

Alternative and improved approaches to the heterologous expression of the proteins ofandare disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.

Heterologous expression of Neisserial proteins

This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteriaB. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and/or nucleic acids.

Neisserial antigenic peptides

This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteriaB. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto (e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and/or nucleic acids.

Alternative and improved approaches to the heterologous expression of the proteins ofand. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.

Heterologous expression of neisserial proteins

Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational antibodies against both L1 proteins upon administration to mice.

Method for producing yeast expressed HPV types 6 and 16 capsid proteins

Growing community of inventors

Poggibonsi, Italy

Cesira Galeotti